Figures




Figure 1



LPS stimulation
TNFa
Toll-like receptor
TNFr1
Traf2
TRADD
RIP
CDK9 inhibitor
CDK9
NIK
Substance P
IKK
Etanercept
Infliximab
Ub
P
IkB
IkB
NfkB
TNFa
Vcam, Icam
IL6
NfkB
CDK9
GR
CDK9 inhibitor
Dexamethasone
nucleus

Figure 2



Suppression of TNFa protein by CDK-inhibiting compound
Reduction [%]
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Cpd 1 10 mg/kg
Cpd 16 10mg/kg

Figure 3



THP-1 in vitro assay
TNFa [% reduction of DMSO control]
60
50
40
30
20
10
0
DMSO
SB203580
BMS345541
cpd 1
cpd 16
cpd 20
cpd 25
treatment

Figure 4A



THP-1 in vitro assay
IL-6 [% reduction of DMSO control]
120
100
80
60
40
20
0
DMSO
SB203580
BMS345541
cpd 1
cpd 16
cpd 20
cpd 25
treatment

Figure 4B